CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to head and neck malignancies.

8:00 am Welcome.
8:05 am HN6 publications update.
- Primary efficacy analysis L. Siu
- Quality of life analysis J. Ringash
- Swallowing sub-study analysis R. Martino
- Pending analysis

Updates on previously discussed proposals
8:20 am Accelerated chemo-radiotherapy with/without Nimorazole in HPV/p16-ve squamous cell head and neck cancer. EORTC 1219/DAHANCA-29 J. Waldron
8:30 am A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck. EORTC-1601-HNCG L. Siu J. Waldron

New Protocol Proposals
9:00 am Randomized phase II study of durvalumab with RT plus maintenance durvalumab versus chemoradiation alone in intermediate risk HPV-positive locoregionally advanced squamous cell of the head and neck (LA-SCCHN) L. Siu J. Waldron
9:30 am Treatment volume de-escalation of radiotherapy for head and neck cancer S. Bratman
9:45 am Other business.
10:00 am Meeting Adjourned.